The PROMETHEUS® IBcause™ Diagnostic Test conveniently brings multiple stool and serum assays together to help identify both infectious and noninfectious potential causes of persistent diarrhea as quickly as possible.

Tests for 14 types of pathogens

IBcause™ allows you to simultaneously test for multiple pathogens that may be present concurrently in patients with persistent diarrhea, including1,2:

  • 8 types of bacteria
  • 3 types of parasites
  • 3 types of viruses

IBcause™ rules out > 90% of acute diarrhea-causing agents4

Fecal calprotectin Predictor of IBD-associated inflammation4

Testing not previously available in the U.S.10

IBcause™ utilizes advanced polymerase chain reaction (PCR)-based amplification technology that makes it faster and more sensitive than conventional culture-based stool-testing methods.1

Fecal calprotectin predictive assay

Fecal calprotectin is a well-known predictor of intestinal inflammation that is associated with inflammatory bowel disease (IBD).3 IBcause™ includes this sensitive stool assay to help you determine the likelihood of potential underlying mucosal inflammatory conditions, such as IBD and infection.

IBcause™ rules out > 90% of acute diarrhea-causing agents4

BAM assay: 7α-hydroxy-4-cholesten-3-one (7C4)

IBcause measures 7C4 levels in patients to help determine if bile acid malabsorption (BAM) is the underlying cause of persistent diarrhea. 7C4 is a marker for measuring the activity of the major rate limiting enzyme in the hepatic bile acid biosynthesis pathway, which is regulated by the CYP7A1 gene.5 Correlation of 7C4 with bile acid synthesis has been validated in multiple studies.6,7

BAM may affect up to 50% of patients with unexplained persistent diarrhea.8 It is often overlooked or misdiagnosed as diarrhea-predominant irritable bowel syndrome (IBS-D).8,9 IBcause™ represents an important advancement for IBS-D patients who fail standard therapy and should be evaluated for possible BAM.10

Fecal calprotectin Predictor of IBD-associated inflammation4

Multiple celiac disease assays

IBcause™ includes several highly sensitive and specific diagnostic serological assays for celiac disease, including11:

  • Anti-endomysial lgA (EMA IgA)
  • Anti-human tissue transglutaminase lgA (tTG IgA)
  • Total serum IgA

The inclusion of total serum IgA testing addresses the needs of your patients who may test negative for celiac disease due to IgA deficiency.11

High-sensitivity C-reactive protein (hsCRP)

IBcause™ also tests for hsCRP, a serological assay for intestinal inflammation. It helps you determine the likelihood of mucosal inflammatory conditions that could be causing persistent diarrhea, such as IBD and infection.

Clear & concise results  
IBcause. Because you want to know what may be irritating the bowel and causing your patients’ persistent diarrhea.

  All in one. All at once.**

*Compared to sequential testing with standard workup for persistent diarrhea.

**Assays can also be ordered separately, and all results should be used in combination with other clinical findings.


  1. 1.DuPont HL. Persistent diarrhea: a clinical review. JAMA. 2016;315(24):2712-2723.

  2. 2.Luminex [package insert]. Toronto, ON, Canada: Luminex Molecular Diagnostics, Inc.; 2014.

  3. 3.Benítez JM, García-Sánchez V. Faecal calprotectin: management in inflammatory bowel disease. World J Gastrointest Pathophysiol. 2015;15;6(4):203-209.

  4. 4.Luminex Corporation. xTAG® Gastrointestinal Pathogen Panel (GPP). 2014.

  5. 5. Russell DW. The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem.2003;72(1):137-174.

  6. 6. Hofmann AF, Mangelsdorf DJ, Kliewer SA. Chronic diarrhea due to excessive bile acid synthesis and not defective ileal transport: a new syndrome of defective fibroblast growth factor 19 release. Clin Gastroenterol Hepatol. 2009;7(11):1151-1154.

  7. 7. Axelson M, Mörk B, Sjövall J. Ethanol has an acute effect on bile acid biosynthesis in man. FEBS Lett.1991;281(1-2):155-159.

  8. 8.Pattni S, Walters JR. Recent advances in the understanding of bile acid malabsorption. Br Med Bull. 2009;92:79-93.

  9. 9.Walters JR. Defining primary bile acid diarrhea: making the diagnosis and recognizing the disorder. Expert Rev Gastroenterol Hepatol. 2010;4(5):561-567.

  10. 10.Camilleri M. Bile acid diarrhea: prevalence, pathogenesis, and therapy. Gut Liver. 2015;9(3):332-339.

  11. 11.Presutti RJ, Cangemi JR, Cassidy HD, Hill DA. Celiac disease. Am Fam Physician. 2007;76(12):1795-1802.